Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Beginning Cash Balance: 2019-2025

Historic Beginning Cash Balance for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $25.4 million.

  • Eton Pharmaceuticals' Beginning Cash Balance rose 43.43% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 8.20%. This contributed to the annual value of $21.4 million for FY2024, which is 31.17% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Beginning Cash Balance stood at $25.4 million, which was up 45.69% from $17.4 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Beginning Cash Balance ranged from a high of $25.8 million in Q3 2021 and a low of $13.4 million during Q4 2022.
  • For the 3-year period, Eton Pharmaceuticals' Beginning Cash Balance averaged around $18.9 million, with its median value being $17.7 million (2024).
  • In the last 5 years, Eton Pharmaceuticals' Beginning Cash Balance soared by 209.72% in 2021 and then crashed by 41.09% in 2022.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' Beginning Cash Balance stood at $22.7 million in 2021, then slumped by 41.09% to $13.4 million in 2022, then surged by 64.97% to $22.1 million in 2023, then dropped by 8.20% to $20.3 million in 2024, then skyrocketed by 43.43% to $25.4 million in 2025.
  • Its Beginning Cash Balance was $25.4 million in Q3 2025, compared to $17.4 million in Q2 2025 and $14.9 million in Q1 2025.